- Home
- HQL vs ALDX Comparison
HQL vs ALDX Comparison
Compare HQL & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQL
- ALDX
- Stock Information
- Founded
- HQL 1992
- ALDX 2004
- Country
- HQL United States
- ALDX United States
- Employees
- HQL N/A
- ALDX N/A
- Industry
- HQL Investment Managers
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- HQL Finance
- ALDX Health Care
- Exchange
- HQL Nasdaq
- ALDX Nasdaq
- Market Cap
- HQL 378.8M
- ALDX 326.6M
- IPO Year
- HQL N/A
- ALDX 2014
- Fundamental
- Price
- HQL $13.75
- ALDX $5.81
- Analyst Decision
- HQL
- ALDX Strong Buy
- Analyst Count
- HQL 0
- ALDX 2
- Target Price
- HQL N/A
- ALDX $9.50
- AVG Volume (30 Days)
- HQL 120.9K
- ALDX 917.6K
- Earning Date
- HQL 01-01-0001
- ALDX 08-07-2025
- Dividend Yield
- HQL 11.56%
- ALDX N/A
- EPS Growth
- HQL N/A
- ALDX N/A
- EPS
- HQL 0.79
- ALDX N/A
- Revenue
- HQL N/A
- ALDX N/A
- Revenue This Year
- HQL N/A
- ALDX N/A
- Revenue Next Year
- HQL N/A
- ALDX $29.89
- P/E Ratio
- HQL $17.08
- ALDX N/A
- Revenue Growth
- HQL N/A
- ALDX N/A
- 52 Week Low
- HQL $11.34
- ALDX $1.14
- 52 Week High
- HQL $14.37
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- HQL 58.71
- ALDX 71.16
- Support Level
- HQL $13.85
- ALDX $5.34
- Resistance Level
- HQL $14.10
- ALDX $5.73
- Average True Range (ATR)
- HQL 0.18
- ALDX 0.27
- MACD
- HQL 0.04
- ALDX 0.01
- Stochastic Oscillator
- HQL 66.67
- ALDX 77.36
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.